PT - JOURNAL ARTICLE AU - Karron, Ruth A. AU - Quesada, Maria Garcia AU - Schappell, Elizabeth A. AU - Schmidt, Stephen D. AU - Knoll, Maria Deloria AU - Hetrich, Marissa K. AU - Veguilla, Vic AU - Doria-Rose, Nicole AU - Dawood, Fatimah S. AU - , TI - Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults AID - 10.1101/2021.12.20.21268034 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.20.21268034 4099 - http://medrxiv.org/content/early/2021/12/21/2021.12.20.21268034.short 4100 - http://medrxiv.org/content/early/2021/12/21/2021.12.20.21268034.full AB - SARS-CoV-2 infections are frequently milder in children than adults, suggesting that immune responses may vary with age. However, information is limited regarding SARS-CoV-2 immune responses in young children. We compared Receptor Binding Domain binding antibody (RBDAb) and SARS-CoV-2 neutralizing antibody (neutAb) in children aged 0-4 years, 5-17 years, and in adults aged 18-62 years in a SARS-CoV-2 household study. Among 55 participants seropositive at enrollment, children aged 0-4 years had >10-fold higher RBDAb titers than adults (373 vs.35, P<0.0001), and the highest RBDAb titers in 11/12 households with seropositive children and adults. Children aged 0-4 years had 2-fold higher neutAb than adults, resulting in higher binding to neutralizing (B/N)Ab ratios compared to adults (1.9 vs. 0.4 for ID50, P=0.0002). Findings suggest that young children mount robust antibody responses to SARS-CoV-2 following community infections. Additionally, these results support using neutAb to measure the immunogenicity of COVID-19 vaccines in children aged 0-4 years.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the U.S. Centers for Disease Control and Prevention (CDC) Award 75D30120C08737.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns Hopkins Bloomberg School of Public Health Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are not openly available due to reasons of sensitivity as they contain personal identifiable information, but are available from the corresponding author (RAK) upon reasonable request.